Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

Related Keywords

Salim Yazji ,Ramesh Narayanan ,Drug Administration ,College Of Medicine ,Oncternal Therapeutics Inc ,University Of Tennessee Health Science Center ,Cancer Research ,Oncternal Therapeutics ,Fast Track ,Muirhead Endowed Professor ,Tennessee Health Science Center ,News ,Prostate Cancer ,